Hi Butcherano, I would say use that TOTAL 40% or greater reduction in Proteinuria as a guide for a clinically meaningful benefit, but the 2 trials are different in both design & drug/s obviously.
Ann: Application for quotation of securities - DXB, page-114
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.030(7.32%) |
Mkt cap ! $242.2M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 45.8¢ | 42.0¢ | $1.241M | 2.815M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21639 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 14976 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |